- Palmer ED, Brick IB. Correlation between the severity of oesophageal varices and their propensity towards haemorrhage. Gastroenterology 1956;30:85-90.
- Liebowitz HR. Pathogenesis of oesophageal varix rupture. JAMA 1961;175:138-45.
- Garcia-Tsao G, Groszmann RJ, Fischer RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of oesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.
- Sauerbruch T, Weinzierl M, Kopeke W, Paumgartner G. Longterm sclerotherapy of bleeding esophageal varices in patients with liver cirrhosis. An evaluation of mortality and rebleeding risk factors. Scand J Gastroenterol 1985;20:51-8.
- Calès P, Pascal JP. Histoire naturelle des varices oesophagienne s au cours de la cirrhose (de la naissance à la rupture). Gastroenterol Clin Biol 1988;12:245-9.
- Kleber G, Sauerbruch T, Ansari H, Paumgartner G. Prediction of variceal hemorrhage. Gastroenterology 1991;100:1332-37.
- Conn HO. Transjugular intrahepatic portal-systemic shunts: the state of the art. Hepatology 1993;17:148-58.
- John TG, Jalan R, Stanley AJ, Redhead DN, Sanfey HA, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt (TIPSS) insertion as a prelude to orthotopic liver transplantation in patients with severe portal hypertension. Eur J GastroHepatol 1996;8:1145-9.
- Kamath PS, McKusick MA, Trans venous intrahepatic portosystemic shunts. Gastroenterology 1996;111:1700-5.
- Rössle M, Haag K, Ochs A, Sellinger M, Noeldge G, Peramau E, et al. The transjugular intrahepatic portosystemic stent-shunt procédure for variceal bleeding. N Engl J Med 1994;330:165-71.
- Stanley AI, Jalan R, Forrest EH, Hayes PC Long-term follow-up of transjugular intrahepatic portosystemic stent shunt (TIFSS) for the treatment of portal hypertension: results in 130 patients. Gut 1996:39:479-85.
- Cabrera J, Mynar M, Granados R, Gortiz G, Kravetz D. Transjugular intrahepatic portasystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996;110:832-9.
- Sanyal AJ, Freedman AM, Luketic VA, Purdum PP, Shiftman ML, Tisnado J, et al. Transjugular intrahepatic portasystemic shunts for the patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996;111:13846.
- Rössle M, Deibert P, Haag K, Ochs A, Olschewski M, Siergerstetter V, et al. Randomized trial of transjugular intrahepatic portasystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997;349: 1043-9.
- Sahagun G, Benner KG, Saxon R, Barton RE, Rabkin J, Keller FS, et al. Outcome of 100 patients after transjugular intrahepatic portasystemic shunt for variceal hemorrhage. Am J Gastroenterol 1997;92:1444-52.
- Sauer P, Theilman L, Stremmel W, Benz C, Richter GM, Stiehl A. Transjugular intrahepatic portasystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997;113:1623-31.
- Sanyal AJ, Freedman AM, Luketic VA, Purdum PP, Shiffman ML, Cole PE, et al. Transjugular intrahepatic portosystemic shunts compared with endoscopie sclerotherapy for prevention of recurrent variceal hemorrhage. A randomized controlled trial. Ann Intern Med 1997;126:849-57.
- Cello JP, Ring EJ, Olcott EW, Koch J, Gordon J, Gordon R, et al. Endoscopie sclerotherapy compared with percutaneaous transjugular intrahepatic portasystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage: a randomized, controlled trial. Ann Intern Med 1997; 126: 858-65.
- D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: ameta-analytic review. Hepatology 1995;22:33254.
- Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99: 1401-7.
- Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol: a medical treatment for portal hypertension? Lancet 1980;2:180-2.
- Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981;305:1371 -4.
- Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995, 346:1056-9.
- Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 1991;324:1532-8.
- Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodes J. Effects of propranolol on azygos blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984;4: 1200-5.
- Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJC, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986;6:101-6.
- Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987;7: 648-53.
- Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982;2:523-7.
- Schepke M, Raab P, Hoppe A, Brensing KA, Paar D, Potyka U, et al. Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. Aliment Pharmacol Ther 1999;13:1451-9.
- Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. Ann Intern Med 1991;114:869-73.
- Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodes J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrat e to propranolol administration in patients with cirrhosis. Hepatology 1990; 11:230.
- Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993;18:477-84.
- Morillas RM, Planas R, Cabre E, Galan A, Quer JC, Feu F, et al. Propranolol plus isosorbide-5-mononitrat e for portai hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 1994;20:1502-8.
- Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites and spontaneous bacterial peritonitis. Gastroenterology 2001; 120:726-48.
- Villanueva C, Balanzo J, Novella MT, Soriano G, Sanz S, Torres X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996:334:1624-9.
- Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, et al. Long-term results of a clinical trial with nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;31:324-9.
- Brensing KA, Neubrand M, Textor J, Raab P, Müller-Miny H, Scheurlen C, et al. Endoscopie manometry of esophageal varices : evaluation of a balloon technique compared with direct portal pressure measurement. J Hepatol 1998;29:94-102.
- Bellis L, Moitinho E, Gonzalez-Abraldes J, Escorsell A, GarciaPagan JC, Rodes J, et al. Propranolol effectively decreases portal pressure in patients with TIPS dysfunction. J Hepatol 2001 ;34 Suppl 1:10A.
- Rockey DC. The cellular pathogenesis of portal hypertension : stellate cell contractility, endothelin and nitric oxide. Hepatology 1997;25:2-5.
- Kroeger RJ, Groszman RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985;5:97-101.
- Escorsell A, Ferayomi L, Bosch J, Garcia-Pagan JC, Garcia-Tsao G, Grace ND, et al. The portal pressure response to B-blockade is greater in cirrhotic patterns without varices than in those with varices. Gastroenterology 1997; 112:2012-6.
- Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
- Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, GarciaVillarreal L, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995;21:986-94.
- Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995;21:709-16.
- Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22.
- Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotic s with hepatorenal syndrome: a phase II study. Gut 2000;47:288-95.
- Michl P, Giilberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure. Scand J Gastroenterol 2000:35:654-8.
- Schepke M, Raab P, Hoppe A, Schiedermaier P, Brensing KA, Sauerbruch T. Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis. Am J Gastroenterol 2000;95:2905-9.
- Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterolog y 2000;118;565-72.
- Girgrah N, Liu P, Collier J, Blendis L, Wong F. Haemodynamic, renal sodium handling, and neurohumoral effects of acute administration of losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. Gut 2000;46:114-20.
- Jalan R, Hayes PC. Sodium handling in patients with wellcompensated cirrhosis is dependent on the severity of liver disease and portal pressure. Gut 2000;46:527-33.
- Bataller R, Gines P, Nicolas JM, Görbig MN, Garcia-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-56.
- Papatheodoridis GV, Coulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopie treatment for prevention of variceal rebleeding : a meta-analysis. Hepatology 1999;30:612-22.
- Luca A, D'Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology 1999;212:411-21.
Scandinavian Journal of Gastroenterology
Volume 37, 2002 - Issue 9